MedTrace Logo

Azacitidine and Homoharringtonine in JMML

NCT04505995 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-08-10

No results posted yet for this study

Summary

Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine, which exhibited a anticancer mechanism and has been widely used in patients with relapse/refractory acute myeloid leukemia (AML). However, the efficacy of these agents has not been elucidated in children with JMML. The primary objective is to assess the treatment effect on response rate in this subject population.

Conditions

  • JMML

Interventions

DRUG

Azacitidine and homoharringtonine

Concommitant use of azacitidine and homoharringtonine

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Taian City Central Hospital

    collaborator OTHER

  • The Affiliated Hospital of Qingdao University

    collaborator OTHER

  • The Second Hospital of Hebei Medical University

    collaborator OTHER

  • Children's Hospital of Hebei Province

    collaborator OTHER

  • Air Force Military Medical University, China

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Month
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2023-01-01
Completion
2025-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04505995 on ClinicalTrials.gov